CD274 and gastric cancer: The PD-L1 positive (CPS ≥ 1%) gastric cancer was reported in approximately 60% in the KEYNOTE-059 and KEYNOTE-061 studies using the same CPS with 22C3 pharmDx assay and 18.2% of the KEYNOTE-061 study was PD-L1 positive (CPS ≥ 10%) gastric cancer.